Maven Securities’s Praxis Precision Medicines PRAX Stock Holding History

Maven Securities’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,000	Closed	-$210K	–	755
2025 Q2	$210K	Buy	+5,000	New	+$190K	0.01%	765
2025 Q1	–	Sell	-5,000	Closed	-$385K	–	953
2024 Q4	$385K	Buy	+5,000	New	+$362K	0.01%	647
2024 Q2	–	Sell	-20,000	Closed	-$1.22M	–	987
2024 Q1	$1.22M	Buy	+20,000	New	+$897K	0.07%	129
2023 Q3	–	Sell	-90,096	Closed	-$1.55M	–	1205
2023 Q2	$1.55M	Buy	+90,096	New	+$1.38M	0.02%	343
2021 Q2	–	Sell	-3,246	Closed	-$1.52M	–	1271
2021 Q1	$1.52M	Buy	3,246 +2,011	+163%	+$1.43M	0.07%	275
2020 Q4	$1.03M	Buy	+1,235	New	+$721K	0.1%	250

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Maven Securities's PRAX Position: Q3 2025 in Review

Maven Securities sold out of Praxis Precision Medicines (PRAX) in Q3 2025, closing a stake of 5,000 shares — an estimated $210K sold.

Maven Securities first reported a position in PRAX in Q4 2020 and held it in 6 quarters. The position peaked at $1.55M in Q2 2023. 152 funds tracked by Wall St. Rank hold PRAX as of Q3 2025.

Maven Securities reported no remaining Praxis Precision Medicines position as of Q3 2025 after selling out during the quarter.
Maven Securities sold 5,000 Praxis Precision Medicines shares in Q3 2025, an estimated $210K.
Maven Securities first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 6 quarters.
Maven Securities's Praxis Precision Medicines position peaked at $1.55M in Q2 2023.
152 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2025.

Based on Maven Securities's 13F filing for Q3 2025, filed 20 Nov 2025.